5-Methoxytryptamine
|
Basic information |
| Metabolite name | 5-Methoxytryptamine |
 | HMDB0004095 |
 |
C05659 |
 |
1833 |
| Synonyms | NA |
| No. of studies | 9 |
|
Basic information |
| Metabolite name | 5-Methoxytryptamine |
| HMDB0004095 |
|
C05659 |
|
1833 |
| Synonyms | NA |
| No. of studies | 9 |
|
Relationship between 5-Methoxytryptamine and depression (count: 9) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
| Study M027 | Type2 | CUMS + QZ group vs. CUMS group | Urine | Wistar rat | Down |
| Study M037 | Type2 | placebo treatment group one-week vs. baseline | Serum | Human | Down |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M783 | Type1 | stroke + CUMS group vs. stroke group | Faece | Sprague-Dawley rat | Up |
| Study M850 | Type1 | reserpine group vs. control group | Brain | C57BL/6 mouse | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Down |